Compare Abeona Therapeutics Inc (ABEO) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nvidia Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Nvidia Corp trades at $218.09 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 12419.6× Abeona Therapeutics Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NVDA | |
|---|---|---|
Market Cap | $424.33M | $5.27T |
Sector | Health | Technology |
52-Week High | $7.45 | $235.75 |
52-Week Low | $4.17 | $165.17 |
Enterprise Value | $279.23M | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
NVIDIA (NVDA) trades at $217.56, down 2.86% over 24 hours, amid a broader tech sell-off. The stock maintains strong fundamentals with Q1 2026 EPS beating estimates at $1.87 and a net income margin of 62.97%. Technical analysis shows a bullish trend with support at $215 and resistance at $222, while RSI indicates neutral momentum.
Outlook remains positive given robust AI-driven revenue growth and a $325.86 analyst price target, but risks include high valuation multiples and competitive pressures. The stock presents a long-term growth opportunity, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
